GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ProPhase Labs Inc (NAS:PRPH) » Definitions » Beneish M-Score
中文

ProPhase Labs (ProPhase Labs) Beneish M-Score : -1.69 (As of Apr. 24, 2024)


View and export this data going back to 1995. Start your Free Trial

What is ProPhase Labs Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.69 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for ProPhase Labs's Beneish M-Score or its related term are showing as below:

PRPH' s Beneish M-Score Range Over the Past 10 Years
Min: -1150.59   Med: -3.04   Max: 3.71
Current: -1.69

During the past 13 years, the highest Beneish M-Score of ProPhase Labs was 3.71. The lowest was -1150.59. And the median was -3.04.


ProPhase Labs Beneish M-Score Historical Data

The historical data trend for ProPhase Labs's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProPhase Labs Beneish M-Score Chart

ProPhase Labs Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -1,150.59 3.71 -2.89 -1.69

ProPhase Labs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.89 -2.49 -2.20 -1.81 -1.69

Competitive Comparison of ProPhase Labs's Beneish M-Score

For the Diagnostics & Research subindustry, ProPhase Labs's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProPhase Labs's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where ProPhase Labs's Beneish M-Score falls into.



ProPhase Labs Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of ProPhase Labs for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 2.708+0.528 * 1.5745+0.404 * 1.6564+0.892 * 0.3619+0.115 * 1.113
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 2.7728+4.679 * -0.059221-0.327 * 1.6543
=-1.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $36.31 Mil.
Revenue was 3.499 + 8.365 + 13.217 + 19.303 = $44.38 Mil.
Gross Profit was -3.056 + 2.327 + 6.448 + 10.52 = $16.24 Mil.
Total Current Assets was $47.59 Mil.
Total Assets was $91.93 Mil.
Property, Plant and Equipment(Net PPE) was $17.47 Mil.
Depreciation, Depletion and Amortization(DDA) was $6.70 Mil.
Selling, General, & Admin. Expense(SGA) was $34.50 Mil.
Total Current Liabilities was $20.86 Mil.
Long-Term Debt & Capital Lease Obligation was $18.59 Mil.
Net Income was -8.751 + -5.141 + -3.44 + 0.55 = $-16.78 Mil.
Non Operating Income was 0.142 + -0.033 + 0.008 + -0.107 = $0.01 Mil.
Cash Flow from Operations was -0.213 + -4.654 + -6.957 + 0.476 = $-11.35 Mil.
Total Receivables was $37.05 Mil.
Revenue was 21.823 + 24.2 + 29.092 + 47.531 = $122.65 Mil.
Gross Profit was 11.283 + 11.973 + 18.72 + 28.677 = $70.65 Mil.
Total Current Assets was $60.83 Mil.
Total Assets was $87.65 Mil.
Property, Plant and Equipment(Net PPE) was $11.35 Mil.
Depreciation, Depletion and Amortization(DDA) was $5.06 Mil.
Selling, General, & Admin. Expense(SGA) was $34.38 Mil.
Total Current Liabilities was $16.08 Mil.
Long-Term Debt & Capital Lease Obligation was $6.66 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(36.313 / 44.384) / (37.054 / 122.646)
=0.818155 / 0.302122
=2.708

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(70.653 / 122.646) / (16.239 / 44.384)
=0.576073 / 0.365875
=1.5745

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (47.585 + 17.47) / 91.927) / (1 - (60.833 + 11.347) / 87.648)
=0.292319 / 0.176479
=1.6564

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=44.384 / 122.646
=0.3619

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(5.061 / (5.061 + 11.347)) / (6.698 / (6.698 + 17.47))
=0.308447 / 0.277143
=1.113

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(34.502 / 44.384) / (34.384 / 122.646)
=0.777352 / 0.280352
=2.7728

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((18.587 + 20.857) / 91.927) / ((6.659 + 16.075) / 87.648)
=0.42908 / 0.259378
=1.6543

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-16.782 - 0.01 - -11.348) / 91.927
=-0.059221

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

ProPhase Labs has a M-score of -1.69 signals that the company is likely to be a manipulator.


ProPhase Labs Beneish M-Score Related Terms

Thank you for viewing the detailed overview of ProPhase Labs's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


ProPhase Labs (ProPhase Labs) Business Description

Traded in Other Exchanges
N/A
Address
711 Stewart Avenue, Suite 200, Garden City, NY, USA, 11530
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
Executives
Morse Robert A. Jr. officer: Controller 711 STEWART AVENUE, SUITE 200, GARDEN CITY NY 11530
Billy Joe White officer: Chief Financial Officer 191 OTTO ST., PORT TOWNSEND WA 98368
Jason Michael Barr director 902 BROADWAY, 15TH FLOOR, NEW YORK NY 10010
Louis Md Gleckel 10 percent owner C/O PROHEALTH CARE ASSOCIATES LLP, 2800 METRUS AVE, LAKE SUCCESS NY 11042
Ted William Karkus 10 percent owner 188 HEWLETT NECK ROAD, WOODMERE NY 11598
Warren Hirsch director 621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Monica L. Brady officer: Chief Accounting Officer 621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Cuddihy Robert V Jr officer: Chief Operating Officer PARKER DURYEE ET AL, 529 FIFTH AVE 8TH FL, NEW YORK NY 10017
Braden Michael Leonard 10 percent owner 156 S. FIRST STREET, ZIONSVILLE IN 46077
Mark S Leventhal 10 percent owner THE BEACON COMPANIES, 50 FEDERAL STREET, BOSTON MA 02468
Mark Shawn Frank director 104 WHISPER WOOD COURT, WRIGHTSTOWN PA 18940
James T Mccubbin director
Mark A. Burnett 10 percent owner 40 HEMLOCK DRIVE, ROSLYN NY 11576
Guy J Quigley director, 10 percent owner, officer: Chairman, President, CEO C/O THE QUIGLEY CORP KELLS BUILDINGS, 621 SHADY RETREAT RD P O BOX 1349, DOYLESTOWN PA 18901
John Deshazo 10 percent owner 17 WOLCOTT COURT, BOSTON MA 02136

ProPhase Labs (ProPhase Labs) Headlines

From GuruFocus

ProPhase Labs Announces Collaboration with Dana-Farber Cancer Institute

By Value_Insider Value_Insider 11-08-2022

ProPhase Labs Acquires Rights to Novel Esophageal Cancer Test

By Value_Insider Value_Insider 12-19-2022

ProPhase Labs to Present at Investor Summit Group's Q4 Conference

By GlobeNewswire GlobeNewswire 11-08-2022